ACV vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. Despite a current price of $27.94 being close to the growth-based intrinsic value of $29.19, the lack of profitability (0% margins across the board), missing financial ratios, and extremely weak technical trend (10/100) undermine valuation support. The 7.73% dividend yield appears attractive but is offset by opaque capital structure and no verifiable payout sustainability metrics. Strong past price performance (+36.2% 1Y) contrasts sharply with deteriorating fundamentals and absence of analyst coverage, suggesting potential value trap dynamics.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
ACV vs BRK-B: Head-to-Head Comparison
This page compares Virtus Diversified Income & Convertible Fund (ACV) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.